Loading provider…
Loading provider…
Pulmonary Disease Physician in Nashville, TN
NPI: 1144312562Primary Practice Location
VANDERBILT UNIVERSITY MEDICAL CENTER
2200 Childrens Way, Nashville, TN
Primary Employer
Spirocare DME LLC
hmpinc.net
HQ Phone
Get MD Lisa's Phone Numberphone_androidMobile
Get MD Lisa's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTN State Medical License
TN State Medical License
1996 - 2027
AL State Medical License
2020 - 2020

American Board of Internal Medicine
Pulmonary Disease
Medical College of Georgia
augusta.edu
Medical School
Until 1993
Vanderbilt University Medical Center
vumc.org
Fellowship • Pulmonary Disease and Critical Care Medicine
1996 - 1999
University of Tennessee (Nashville)
Residency • Internal Medicine
1993 - 1996
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 94010Measurement and graphic recording of total and timed exhaled air capacity | 238 | 299 |
| 2 | 94729Measurement of lung diffusing capacity | 229 | 284 |
| 3 | 94726Determination of lung volumes using plethysmography | 135 | 156 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 63 | 68 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 58 | 89 |
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis.
Authors: Jonathan Goldin, David Hotchkin, Christopher Ryerson, Jonathan Ilowite
Publication Date: 2020-09
Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real-world patient data repository.
Authors: Harrison Farber, Murali Chakinala, Ronald Oudiz
Publication Date: 2023-07
Lead Sponsor: Fernando J Martinez
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), University of Michigan, University of Virginia, Pulmonary Fibrosis Foundation, University of Washington, Three Lakes Foundation
Intervention / Treatment: DRUG: Placebo, DRUG: N-acetyl cysteine
Lead Sponsor: Galecto Biotech AB
Collaborators: Syneos Health, bioRASI, LLC
Intervention / Treatment: DRUG: Placebo, DRUG: GB0139
Lead Sponsor: FibroGen
Intervention / Treatment: DRUG: Placebo, DRUG: Sub-Study: Nintedanib, DRUG: Pamrevlumab, DRUG: Sub-Study: Pirfenidone